Xenograft tumor models are known to preserve original tumor characteristics including, clinical biomolecular signature, tumor archive, heterogeneous histology, and malignant phenotypes and génotypes, among others.
Frequently Asked Questions
The market is segmented based on Global Patient Derived Xenograft (PDX) Models Market Segmentation, By Type (Mice Models, Rat Models), Tumor Type (Respiratory Tumor Models, Urological Tumor Models, Gastrointestinal Tumor Models, Hematological Tumor Models, Gynecological Tumor Models, Others), Application (Preclinical Drug Development and Oncology Research, Biomarker Analysis), End User (Contract Research Organization, Academic and Research Institutions, Pharmaceutical and Biotechnology Companies) – Industry Trends and Forecast to 2031
.
The Global Pdx Models Market size was valued at USD 194.95 USD Billion in 2023.
The Global Pdx Models Market is projected to grow at a CAGR of 17.01% during the forecast period of 2024 to 2031.
The major players operating in the market include Crown Bioscience , THE JACKSON LABORATORY, Champions Oncology , Charles River Laboratories, Wuxi AppTec, and others-.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
